• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Barclay’s downgrades Edwards Lifesciences

Barclay’s downgrades Edwards Lifesciences

September 26, 2011 By MassDevice staff

Edwards Lifesciences

Barclay’s, the British investment bank, downgraded Edwards Lifesciences (NYSE:EW) shares last week, saying the market for transcatheter aortic valve replacement devices might not be as robust as the company hopes.

Edwards is ahead in the race to bring an artificial aortic replacement valve to the U.S. market with its Sapien device. But the company has received mixed messages from Wall Street, with some analysts downgrading Edwards’ stock and others more bullish on its prospects.

Barclay’s downgraded EW shares from “overweight” to “equal weight” Sept. 23, on fears that the stock will be volatile should the FDA clear the device as expected this fall. The bank also lowered its price target from $95 to $85 for EW shares.

Sign up to get our free newsletters delivered straight to your inbox

“Net-net, while we continue to be positive on the long-term potential of the TAVR market, we think that the market could be slower to develop and upcoming risks could cause the stock to retrace,” the analysts wrote, according to StreetInsider.com.

Analysts at Rodman & Renshaw are also bearish on EW shares. Last month that firm downgraded the stock from a “market perform” rating to “underperform” in a research note to investors. The investment bank put a $66.00 target on the stock, which opened at $77.89 yesterday. Rodman & Renshaw’s price targets are significantly lower than other analysts’ forecasts on The Street. Morgan Keenan upgraded EW shares to “outperform” from “market perform” with a target price of $97.00 yesterday. And last week, Bank of America Merrill Lynch reiterated its “neutral” rating on the stock with a target of $99.00.

EW shares were up slightly this morning as of about 10 a.m., trading around the $75 mark.

Filed Under: News Well, Replacement Heart Valves, Wall Street Beat Tagged With: Barclay's, Edwards Lifesciences

More recent news

  • A new way to monitor glucose: Glucotrack explains 3-year CBGM implant technology
  • Dexcom continues advances in AI for CGM, type 2 diabetes awareness
  • Tandem continues to deliver more options, benefits for those with diabetes
  • Breaking: Sequel to launch twiist automated insulin delivery system next month
  • Dexcom shares U.S. report on CGM benefits for type 2 diabetes

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy